Pure Global
NCT05677035

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

A Single-center, Open-label, Parallel-group, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects
Hyundai Pharm·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Contraception
Drug/Device/Intervention
LINO-1713 1 tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hyundai Pharm
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
Jan 11, 2022
End date
Jun 15, 2022
Enrollment
20 participants
Primary outcome

Pharmacokinetics parameters: Cmax,Pharmacokinetics parameters: Tmax

Summary

A single-center, open-label, parallel-group, phase 1 study to assess the safety,
 tolerability, pharmacokinetics, and pharmacodynamics of LINO-1713 in healthy Korean female
 subjects

ICD-10 classifications
Contraceptive managementOral contraceptivesOther contraceptive managementGeneral counselling and advice on contraceptionPersonal history of contraception
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05677035
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05677035 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hyundai Pharm and is currently Completed. The study focuses on Contraception. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.